Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Thromboembolic events can occur after musculoskeletal injury and related surgery

Below is a news summary of an orthopaedic research study appearing in the March 21, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issues' full Table of Contents.

22 Mar 2012

Addition of two MRI sequences to MRPA improves detection of pulmonary embolism

New research shows that the addition of two magnetic resonance imaging (MRI) sequences to a common MR angiography technique significantly improves detection of pulmonary embolism, a potentially life-threatening condition traditionally diagnosed through computed tomography.

19 Mar 2012

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

16 Mar 2012

Researchers identify variation in head CT use among ED doctors

A new study by Brigham and Women's Hospital (BWH) researchers found significant variation in the use of head computed tomography (CT) exams among doctors within the emergency department.

13 Mar 2012

Elevated risk of PE occurs within first 7 days after total joint replacement surgery

The elevated risk of pulmonary embolism (PE) - a blood clot that travels from the leg to the lungs - following total joint replacement (TJR) surgery has been well established, yet little is known about the natural course and timing of this potentially fatal condition.

8 Feb 2012

Anticoagulation drugs can prevent PE, DVT after total joint replacement

Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs.

7 Feb 2012

New guidelines for travellers to avoid DVT on long flights

New guidelines for travellers have been issued. Experts warn that those with a higher risk of serious blood clots who opt for the window seat on flights longer than four hours are potentially putting themselves in danger. People who should be most concerned are those who have recently had surgery, cancer patients, those with limited mobility, the severely obese, and travellers over 70. However, healthy women on the pill and those who are pregnant should also be careful, according to the guidelines by the American College of Chest Physicians.

7 Feb 2012

New ACCP guidelines address DVT/PE risk factors for long-distance travel

New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.

7 Feb 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Crux receives CE mark approval for inferior vena cava filter with BDR

Crux Biomedical announced it has received CE mark approval for their revolutionary inferior vena cava filter (IVCF) with bi-directional retrieval (BDR). Vena cava filters are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). Each year in the United States, approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur.

23 Jan 2012

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe.

17 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Research examines novel treatment techniques for hemophilia B, VTE

Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

VDF, CDC and VDC to educate women about gender-specific DVT risks

Deep vein thrombosis (DVT) is a blood clot in the deep veins in the legs. These clots can break loose and travel to the lungs, causing a potentially fatal pulmonary embolism (PE). Even when they don't, they can cause permanent damage to the leg veins that results in long-term pain, swelling, and disability of the leg.

9 Dec 2011

Factors associated with increased risk of in-hospital falls after total hip or knee replacement surgery

Investigators from Hospital for Special Surgery have identified factors that are associated with an increased risk of in-hospital falls after total hip or knee replacement surgery.

5 Dec 2011

IVC filter study reinforces SIR's guidelines surrounding retrieval or permanent placement

Researchers have published the largest single patient population study to date on a method for following patients with retrievable inferior vena cava (IVC) filters-devices used to keep blood clots from traveling to the lungs.

29 Nov 2011

Pulmonary Embolism News and Research

Further Reading

Thromboembolic events can occur after musculoskeletal injury and related surgery

Addition of two MRI sequences to MRPA improves detection of pulmonary embolism

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

Researchers identify variation in head CT use among ED doctors

Elevated risk of PE occurs within first 7 days after total joint replacement surgery

Anticoagulation drugs can prevent PE, DVT after total joint replacement

New guidelines for travellers to avoid DVT on long flights

New ACCP guidelines address DVT/PE risk factors for long-distance travel

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Crux receives CE mark approval for inferior vena cava filter with BDR

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

Research examines novel treatment techniques for hemophilia B, VTE

VDF, CDC and VDC to educate women about gender-specific DVT risks

Factors associated with increased risk of in-hospital falls after total hip or knee replacement surgery

IVC filter study reinforces SIR's guidelines surrounding retrieval or permanent placement

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News